You are here

Article Text

Article menu
Download PDFPDF
Unexpected outcome (positive or negative) including adverse drug reactions
CASE REPORT
Rare side effect of adjuvant ipilimumab after surgical resection of melanoma: Guillain-Barré syndrome
  1. Rohini J Patel,
  2. Michael A Liu,
  3. Akshay Amaraneni,
  4. Simran K Sindhu
  1. Division of Hematology-Oncology, The University of Arizona Cancer Center, Tucson, Arizona, USA
  1. Correspondence to Rohini J Patel, rohinipatel{at}email.arizona.edu

Summary

Guillain-Barré syndrome is a life-threatening neurological disorder that presents with rapid ascending paralysis and areflexia. Guillain-Barré syndrome is traditionally associated with infections from a gastrointestinal or respiratory tract source. We report the case of a 71-year-old man with melanoma who was treated with ipilimumab as adjuvant immunotherapy and subsequently developed Guillain-Barré syndrome. The diagnosis was made clinically through physical exam findings. He was successfully treated with a combination of intravenous immunoglobulin therapy and corticosteroids.

  • unwanted effects / adverse reactions
  • cancer intervention
  • peripheral nerve disease
  • skin cancer
  • chemotherapy

https://doi.org/10.1136/bcr-2017-221318

Statistics from Altmetric.com

    Request Permissions

    If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

    View Full Text

    Footnotes

    • Contributors RJP: analysis of current literature as it relates to case, drafting manuscript, critical revision of manuscript, final approval of version to be published. MAL: critical revision of manuscript, final approval of version to be published. AA: designed treatment plan and clinical recommendations, critical revision of manuscript, final approval of version to be published. SKS: designed treatment plan and clinical recommendations, analysis of current literature as it relates to case, drafting manuscript, critical revision of manuscript, final approval of version to be published.

    • Competing interests None declared.

    • Patient consent Obtained.

    • Provenance and peer review Not commissioned; externally peer reviewed.